As next-generation sequencing (NGS) platforms advance in their speed, ease-of-use, and cost-effectiveness, many translational researchers are transitioning from microarrays to RNA sequencing (or RNA-seq) for their gene expression analysis needs. RNA-seq goes beyond differential gene expression to provide fundamental insights into how genomes are organized and regulated. New RNA-seq solutions now offer higher sensitivity, increased sample number flexibility, and the ability to analyze highly degraded or rare samples from as little as 10 ng of input RNA. Dr. Bramlett will discuss how NGS and RNA-seq can be applied for the discovery of new tumor biomarkers in archived formalin-fixed, paraffin-embedded (FFPE) samples.